Haw Par Corporation Limited (HAWPY)
USD 28.64
(0.0%)
USD 28.64
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 216.56 Million SGD | 46.02% |
| 2022 | 148.31 Million SGD | 34.71% |
| 2021 | 110.1 Million SGD | -8.07% |
| 2020 | 119.77 Million SGD | -34.27% |
| 2019 | 182.2 Million SGD | 1.75% |
| 2018 | 179.06 Million SGD | 46.23% |
| 2017 | 122.46 Million SGD | -2.06% |
| 2016 | 125.04 Million SGD | -31.77% |
| 2015 | 183.27 Million SGD | 54.24% |
| 2014 | 118.82 Million SGD | 10.11% |
| 2013 | 107.91 Million SGD | -10.04% |
| 2012 | 119.96 Million SGD | 50.32% |
| 2011 | 79.8 Million SGD | -29.06% |
| 2010 | 112.5 Million SGD | 97.26% |
| 2009 | 57.03 Million SGD | -27.13% |
| 2008 | 78.26 Million SGD | -50.77% |
| 2007 | 158.98 Million SGD | 48.46% |
| 2006 | 107.09 Million SGD | 33.35% |
| 2005 | 80.31 Million SGD | 9.63% |
| 2004 | 73.25 Million SGD | 47.37% |
| 2003 | 49.7 Million SGD | 174.12% |
| 2002 | 18.13 Million SGD | -42.78% |
| 2001 | 31.69 Million SGD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 60.99 Million SGD | 8.51% |
| 2024 Q2 | 60.99 Million SGD | 0.0% |
| 2023 Q1 | 52.07 Million SGD | 46.48% |
| 2023 Q4 | 56.21 Million SGD | 0.0% |
| 2023 FY | 216.56 Million SGD | 46.02% |
| 2023 Q2 | 52.07 Million SGD | 0.0% |
| 2023 Q3 | 56.21 Million SGD | 7.96% |
| 2022 Q4 | 35.54 Million SGD | 0.0% |
| 2022 FY | 148.31 Million SGD | 34.71% |
| 2022 Q1 | 38.61 Million SGD | -32.41% |
| 2022 Q2 | 77.22 Million SGD | 100.0% |
| 2022 Q3 | 35.54 Million SGD | -53.97% |
| 2021 Q1 | 26.48 Million SGD | -8.0% |
| 2021 Q4 | 57.12 Million SGD | 100.0% |
| 2021 Q3 | 28.56 Million SGD | -46.08% |
| 2021 Q2 | 52.97 Million SGD | 100.0% |
| 2021 FY | 110.1 Million SGD | -8.07% |
| 2020 Q1 | 45.49 Million SGD | 253.19% |
| 2020 Q3 | 14.39 Million SGD | -84.18% |
| 2020 FY | 119.77 Million SGD | -34.27% |
| 2020 Q4 | 28.79 Million SGD | 100.0% |
| 2020 Q2 | 90.98 Million SGD | 100.0% |
| 2019 FY | 182.2 Million SGD | 1.75% |
| 2019 Q4 | 12.88 Million SGD | -77.33% |
| 2019 Q3 | 56.8 Million SGD | -37.2% |
| 2019 Q2 | 90.45 Million SGD | 309.83% |
| 2019 Q1 | 22.07 Million SGD | 7.92% |
| 2018 Q1 | 19.34 Million SGD | 22.3% |
| 2018 Q4 | 20.45 Million SGD | -64.26% |
| 2018 Q3 | 57.21 Million SGD | -30.27% |
| 2018 Q2 | 82.05 Million SGD | 324.3% |
| 2018 FY | 179.06 Million SGD | 46.23% |
| 2017 FY | 122.46 Million SGD | -2.06% |
| 2017 Q4 | 15.81 Million SGD | -60.37% |
| 2017 Q3 | 39.9 Million SGD | -22.21% |
| 2017 Q2 | 51.29 Million SGD | 207.55% |
| 2017 Q1 | 16.68 Million SGD | -3.35% |
| 2016 Q4 | 17.25 Million SGD | -59.26% |
| 2016 FY | 125.04 Million SGD | -31.77% |
| 2016 Q3 | 42.35 Million SGD | -12.4% |
| 2016 Q2 | 48.35 Million SGD | 240.82% |
| 2016 Q1 | 14.18 Million SGD | -25.4% |
| 2015 FY | 183.27 Million SGD | 54.24% |
| 2015 Q4 | 19.01 Million SGD | -45.54% |
| 2015 Q3 | 34.92 Million SGD | -69.86% |
| 2015 Q2 | 115.87 Million SGD | 761.22% |
| 2015 Q1 | 13.45 Million SGD | -26.6% |
| 2014 Q3 | 26.64 Million SGD | -56.81% |
| 2014 Q4 | 18.33 Million SGD | -31.19% |
| 2014 Q1 | 12.16 Million SGD | -49.09% |
| 2014 FY | 118.82 Million SGD | 10.11% |
| 2014 Q2 | 61.68 Million SGD | 407.05% |
| 2013 Q1 | 7.65 Million SGD | -77.84% |
| 2013 Q3 | 22.35 Million SGD | -58.62% |
| 2013 Q2 | 54.01 Million SGD | 605.83% |
| 2013 FY | 107.91 Million SGD | -10.04% |
| 2013 Q4 | 23.89 Million SGD | 6.91% |
| 2012 Q1 | 7.29 Million SGD | -51.7% |
| 2012 Q3 | 20.48 Million SGD | -53.95% |
| 2012 Q4 | 34.54 Million SGD | 68.58% |
| 2012 FY | 119.96 Million SGD | 50.32% |
| 2012 Q2 | 44.49 Million SGD | 510.12% |
| 2011 Q4 | 15.09 Million SGD | 102.33% |
| 2011 Q1 | 6.56 Million SGD | -76.3% |
| 2011 Q2 | 51.65 Million SGD | 686.87% |
| 2011 FY | 79.8 Million SGD | -29.06% |
| 2011 Q3 | 7.46 Million SGD | -85.55% |
| 2010 Q2 | 47.61 Million SGD | 553.64% |
| 2010 Q4 | 27.69 Million SGD | -7.45% |
| 2010 FY | 112.5 Million SGD | 97.26% |
| 2010 Q3 | 29.92 Million SGD | -37.16% |
| 2010 Q1 | 7.28 Million SGD | 143.01% |
| 2009 Q1 | 9.04 Million SGD | 0.0% |
| 2009 Q4 | -16.93 Million SGD | -176.71% |
| 2009 Q3 | 22.07 Million SGD | -48.48% |
| 2009 Q2 | 42.84 Million SGD | 373.54% |
| 2009 FY | 57.03 Million SGD | -27.13% |
| 2008 FY | 78.26 Million SGD | -50.77% |
| 2007 FY | 158.98 Million SGD | 48.46% |
| 2006 FY | 107.09 Million SGD | 33.35% |
| 2005 FY | 80.31 Million SGD | 9.63% |
| 2004 FY | 73.25 Million SGD | 47.37% |
| 2003 FY | 49.7 Million SGD | 174.12% |
| 2002 FY | 18.13 Million SGD | -42.78% |
| 2002 Q2 | 23.5 Million SGD | 0.0% |
| 2002 Q4 | -5.21 Million SGD | 0.0% |
| 2001 FY | 31.69 Million SGD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| AstraZeneca PLC | 5.95 Billion USD | 96.363% |
| Bristol-Myers Squibb Company PFD CONV 2 | 8.02 Billion USD | 97.301% |
| CSPC Pharmaceutical Group Limited | 830.91 Million USD | 73.936% |
| Clarus Therapeutics Holdings, Inc. | -56.51 Million USD | 483.227% |
| Novartis AG | 14.85 Billion USD | 98.542% |
| PT Kalbe Farma Tbk. | 179.7 Million USD | -20.513% |